Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Ning

Showing results (621-630 of 657) with videos related to

Pageof 66
Sort By:
The Journal of Physiology|November 30, 2014
In vivo roles for myosin phosphatase targeting subunit-1 phosphorylation sites T694 and T852 in bladder smooth muscle contractionCai-Ping Chen, Xin Chen, Yan-Ning Qiao, et al.
International Journal of Cancer|April 4, 2017
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trialMarta Schirripa, Wu Zhang, Volker Heinemann, et al.
Drug Delivery|February 26, 2019
Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteinsXiao-Qin Liu, Hong-Yi Xin, Yan-Ning Lyu, et al.
Clinical Colorectal Cancer|April 12, 2018
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) StudyDiana L Hanna, Fotios Loupakis, Dongyun Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trialsMartin D Berger, Yan Ning, Sebastian Stintzing, et al.
International Journal of Cancer|June 2, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancerSatoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, et al.
Clinical Colorectal Cancer|April 3, 2018
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With RegorafenibMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Molecular Cancer Therapeutics|August 7, 2013
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United StatesTakeru Wakatsuki, Melissa J LaBonte, Pierre O Bohanes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/CetuximabMartin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine|February 18, 2016
[Analysis of Applying Chinese Medical Clinical Pathway for Treating Attention-deficit Hyperactivity Disorder]Yu-qing Guo, Xin-min Han, Xian-kang Zhu, et al.
Pageof 66

Showing results (621-630 of 657) with videos related to

Sort By:
Pageof 66
The Journal of Physiology|November 30, 2014
In vivo roles for myosin phosphatase targeting subunit-1 phosphorylation sites T694 and T852 in bladder smooth muscle contractionCai-Ping Chen, Xin Chen, Yan-Ning Qiao, et al.
International Journal of Cancer|April 4, 2017
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trialMarta Schirripa, Wu Zhang, Volker Heinemann, et al.
Drug Delivery|February 26, 2019
Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteinsXiao-Qin Liu, Hong-Yi Xin, Yan-Ning Lyu, et al.
Clinical Colorectal Cancer|April 12, 2018
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) StudyDiana L Hanna, Fotios Loupakis, Dongyun Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trialsMartin D Berger, Yan Ning, Sebastian Stintzing, et al.
International Journal of Cancer|June 2, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancerSatoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, et al.
Clinical Colorectal Cancer|April 3, 2018
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With RegorafenibMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Molecular Cancer Therapeutics|August 7, 2013
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United StatesTakeru Wakatsuki, Melissa J LaBonte, Pierre O Bohanes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/CetuximabMartin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine|February 18, 2016
[Analysis of Applying Chinese Medical Clinical Pathway for Treating Attention-deficit Hyperactivity Disorder]Yu-qing Guo, Xin-min Han, Xian-kang Zhu, et al.
Pageof 66